✦ LIBER ✦

Current state of stem cell research for the treatment of Parkinson's disease

✍ Scribed by M. Gerlach; H. Braak; A. Hartmann; W. H. Jost; P. Odin; J. Priller; J. Schwarz

Publisher: Springer
Year: 2002
Tongue: English
Weight: 149 KB
Volume: 249
Category: Article
ISSN: 0340-5354
DOI: 10.1007/s00415-002-1307-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Stem cell-based therapies in Parkinson’s

Stem cell-based therapies in Parkinson’s disease: future hope or current treatment option?

✍ Kai Loewenbrück; Alexander Storch 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 184 KB

Human ES and iPS cells as cell sources f

Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: Current state and problems

✍ Dong-Youn Hwang; Dae-Sung Kim; Dong-Wook Kim 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB

## Abstract Cell therapy using human embryonic stem cells (hESCs) is a promising therapeutic option for Parkinson's disease (PD), an incurable neurodegenerative disease. A prerequisite for clinical application of hESCs for PD is an efficient and strict differentiation of hESCs into midbrain dopamin

From bench to bed: the potential of stem

From bench to bed: the potential of stem cells for the treatment of Parkinson’s disease

✍ Asuka Morizane; Jia-Yi Li; Patrik Brundin 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 392 KB

Levodopa in the treatment of Parkinson's

Levodopa in the treatment of Parkinson's disease: Current controversies

📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 27 KB 👁 1 views

## Abstract The original article to which this Erratum refers was published in the September, 2004 issue of __Movement__ Disorders (2004) 19 (9) 997–1005.

Levodopa in the treatment of Parkinson's

Levodopa in the treatment of Parkinson's disease: Current controversies

✍ C. Warren Olanow; Yves Agid; Yoshi Mizuno; Alberto Albanese; U. Bonucelli; Phili 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 1 views

## Abstract Levodopa is the most effective symptomatic agent in the treatment of Parkinson's disease (PD) and the “gold standard” against which new agents must be compared. However, there remain two areas of controversy: (1) whether levodopa is toxic, and (2) whether levodopa directly causes motor

Levodopa in the treatment of Parkinson's

Levodopa in the treatment of Parkinson's disease: Current controversies

✍ Manfred Gerlach; Heinz Reichmann; Peter Riederer 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 39 KB 👁 1 views

## Abstract Companion letters have been published in __Movement__ Disorders: Current Controversies: Levodopa in the Treatment of Parkinson's Disease, by Sharma, Vassallo, and Ross and Reply: Levodopa in the Treatment of Parkinson's Disease, by Olanow, Agid, and Mizuno.